API
< Back to all clusters
[HEALTH] · Germany, United Kingdom · 6 sources

started · updated

InfectoPharm launches OtoAir nasal balloon devices for ear ventilation

InfectoPharm Arzneimittel and Consilium GmbH announced the market launch of two new medical devices, the OtoAir® nasal balloon and the OtoAir® soft nasal balloon, on 30 July 2026. The products are listed as reimbursable aids under the German statutory health insurance (GKV) and are intended for non‑invasive treatment of middle‑ear ventilation disorders such as otitis media with effusion (Paukenerguss).

The standard OtoAir® balloon is suitable for patients aged three years and older, while the soft version is designed for children from two years, offering a lower inflation pressure. Each kit contains one nasal piece and six balloons and carries a QR code linking to a child‑friendly instructional video. Clinical guidelines, including the DGPI handbook, endorse nasal‑balloon ventilation as a conservative therapy for middle‑ear effusion.

The devices are marketed for use in adults and children, including scenarios such as pressure changes during flying or diving, and are positioned as a gentle alternative to more invasive interventions.

Entities

Consilium GmbH · DGPI · German statutory health insurance (GKV) · InfectoPharm Arzneimittel · OtoAir Nasal Balloon

Claims

What the coverage asserts, and how many sources carry each claim.